IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation

Xinhui Ni,Yi Xu,Wang Wang,Baida Kong,Jian Ouyang,Jiwei Chen,Man Yan,Yawei Wu,Qi Chen,Xinxin Wang,Hongquan Li,Xiaoguang Gao,Hongquan Guo,Lian Cui,Zeyu Chen,Yuling Shi,Ronghui Zhu,Wei Li,Tieliu Shi,Lin-Fa Wang,Jinling Huang,Chen Dong,Yuping Lai

DOI: https://doi.org/10.1038/s41590-022-01339-3

2022-10-22

Pathogenesis

Abstract:Abstract Aberrant RNA splicing in keratinocytes drives inflammatory skin disorders. In the present study, we found that the RNA helicase DDX5 was downregulated in keratinocytes from the inflammatory skin lesions in patients with atopic dermatitis and psoriasis, and that mice with keratinocyte-specific deletion of Ddx5 ( Ddx5 ∆KC ) were more susceptible to cutaneous inflammation. Inhibition of DDX5 expression in keratinocytes was induced by the cytokine interleukin (IL)-17D through activation of the CD93–p38 MAPK–AKT–SMAD2/3 signaling pathway and led to pre-messenger RNA splicing events that favored the production of membrane-bound, intact IL-36 receptor (IL-36R) at the expense of soluble IL-36R (sIL-36R) and to the selective amplification of IL-36R-mediated inflammatory responses and cutaneous inflammation. Restoration of sIL-36R in Ddx5 ∆KC mice with experimental atopic dermatitis or psoriasis suppressed skin inflammation and alleviated the disease phenotypes. These findings indicate that IL-17D modulation of DDX5 expression controls inflammation in keratinocytes during inflammatory skin diseases.